Outcomes, Safety and Tolerability of Sacubitril-Valsartan over 3 years of Follow-up in Canadian Practice: Insights from the PARTHENON Registry
The PARTHENON registry confirms the safety and tolerability of sacubitril-valsartan in patients with HFrEF in a real-world setting. The registry also demonstrated improvement in left ventricular ejection fraction, and a lower mortality rate, compared to the predicted mortality rate in this population.
Authors
- Jonathan G. Howlett (ORCID: https://orcid.org/0000-0002-0535-9771)
- Melanie Kok (ORCID: https://orcid.org/0000-0002-4553-8096)
- Carlos Rojas‐Fernandez
- Justin Adrian Ezekowitz (ORCID: https://orcid.org/0000-0002-2724-4086)
- Anique Ducharme
- Michael McDonald (ORCID: https://orcid.org/0000-0002-8026-9274)
- Jacob A. Udell (ORCID: https://orcid.org/0000-0001-7402-9584)
Institutions
- University of Calgary (CA)
- Montreal Heart Institute (CA)
- Women's College Hospital (CA)
- Women and Children’s Health Research Institute (CA)
- San Diego Cardiac Center (US)
- Novartis (Canada) (CA)
- Libin Cardiovascular Institute of Alberta (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- CJC Open
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.cjco.2025.10.007
- Citations
- 1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Alnylam Pharmaceuticals
- Cytokinetics
- Novo Nordisk
- Servier
- Novartis Pharmaceuticals Canada
- American Regent